ESC Journals Track: Come along on Saturday, 26 August to The Hub – Mondrian for a star-studded journals-dedicated day around the theme of HF. Then, step into the future on Sunday morning when EHJ - Digital Health presents their most influential articles on the Digital Health stage.
Simultaneous publications: A continuously updated list of cutting-edge articles and ESC Guidelines published at the same time as their related congress sessions.
Top-cited articles: Access those articles most cited by you, the cardiovascular community, and see what you have considered cite-worthy across our entire journal family.
In Amsterdam?: See what we are doing at the congress and where to meet us.
Updates from our publishers: Links to our publisher’s’ congress pages where immediate (post-embargo) access to simultaneous publications is possible, as well as a host of other offers and services.
Journal sessions not to be missed
On 26 August
The ESC Journal Family: focus on heart failure
Joint session with the European Heart Journal (EHJ)
European Heart Journal - Desmond Julian Award
Joint session with the European Heart Journal (EHJ)
The EHJ’s year in cardiovascular medicine: dyslipidaemias, imaging, ischaemic heart disease
Joint session with the European Heart Journal (EHJ)
Ageing in the heart of Cardiovascular Research: from basic mechanisms to clinical targeting
Joint session with the European Heart Journal (EHJ) - Cardiovascular Research
The EHJ’s year in cardiovascular medicine: cardio-oncology, heart failure, and arrhythmias
Joint session with the European Heart Journal (EHJ)
On 27 August
The best of The European Heart Journal – Digital Health 2022-2023
Joint session with the European Heart Journal - Digital Health (EHJ - DH)
Simultaneous Publications
21 August
- At 08:00 - EJHF - Baseline characteristics of patients enrolled in the EMPACT-MI trial - Josephine Harrington
- At 08:00 - EJHF - Sex Differences in Long-term Outcomes Following Heart Failure Hospitalization Across a Spectrum of Ejection Fraction: Findings from the Get With The Guidelines - Heart Failure Registry - Neil Keshvani
25 August
- At 05:10 - EuroIntervention - Transcatheter interventions for left-sided valvular heart disease complicated by cardiogenic shock: a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) in collaboration with the Association for Acute Cardiovascular Care (ACVC) and the ESC Working Group on Cardiovascular Surgery. - Chiara Fraccaro et al.
- At 08:30 - EHJ - Competency-based cardiac imaging for patient-centred care. A statement of the European Society of Cardiology (ESC). With the contribution of the European Association of Cardiovascular Imaging (EACVI), and the support of the Association of Cardiovascular Nursing & Allied Professionals (ACNAP), the Association for Acute CardioVascular Care (ACVC), the European Association of Preventive Cardiology (EAPC), the European Association of Percutaneous Cardiovascular Interventions (EAPCI), the European Heart Rhythm Association (EHRA), and the Heart Failure Association (HFA) of the ESC - Steffen E. Petersen
- At 08:30 - EHJ - Guidelines - Acute Coronary Syndromes - Robert Byrne and Borja Ibanez
- At 08:30 - EHJ - Guidelines - Cardiomyopathies - Elena Arbelo and Juan Pablo Kaski
- At 08:30 - EHJ - Guidelines - Cardiovascular disease and diabetes - Nikolaus Marx and Massimo Federici
- At 08:30 - EHJ - Guidelines - Endocarditis - Victoria Delgado and Michael Borger
- At 08:30 - EHJ - Guidelines - Focused update of the 2021 heart failure guidelines - Theresa McDonagh and Marco Metra
- At 09:45 - EHJ - Renal Function and Decongestion With Acetazolamide in Acute Decompensated Heart Failure and Renal Function: A Prespecified Analysis From the ADVOR Trial - Evelyne Meekers (Wilfried Mullens, author)
- At 09:45 - EHJ - Acetazolamide for Acute Heart Failure: Is ADVOR a Riddle Wrapped in a Mystery Inside an Enigma? - Héctor Bueno
- At 12:15 - EHJ - Temporal trends of cause-specific mortality after diagnosis of atrial fibrillation - Jianhua Wu
- At 12:15 - EHJ - Adverse outcomes in patients with atrial fibrillation: how previous successes can unmask new challenges - David Conen
- At 14:30 - EHJ - TRI-SCORE and benefit of intervention in patients with severe tricuspid regurgitation - Julien Dreyfus
- At 15:00 - EHJ - Atrial fibrillation progression after cryoablation versus radiofrequency ablation: the CIRCA-DOSE trial - Jason Andrade
26 August
- At 8.30 - EHJ- High Costs of Cardiovascular Disease in the European Union - William Weintraub
- At 8.30 - EHJ- Economic burden of cardiovascular diseases in the European Union in 2021: a population-based cost study - Jose Leal
- At 09:30 - EHJ - Plasma cholesterol levels in infancy: a neglected resource - Kirsten Bjørklund Holven
- At 09:30 - EHJ - Significance of lipids, lipoproteins, and apolipoproteins during the first 14-16 months of life - Ruth Frikke-Schmidt
- At 09:30 - EHJ - Efficacy of ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis - Piotr Ponikowski
- At 09:45 - EHJ - Upgrade of right ventricular pacing to cardiac resynchronisation therapy in heart failure: a randomised trial - Bela Merkely
- At 09:45 - EHJ - The BUDAPEST trial: a good grade for upgrades in heart failure with reduced ejection fraction - Cecilia Linde
- At 14:15 - EHJ Open - Aortic Flow is Associated with Ageing and Exercise Capacity - Liang Zhong
- At 15:30 - EJHF - Influence of background medical therapy on efficacy and safety of dapagliflozin in patients with heart failure with improved ejection fraction in the DELIVER trial - Maria Pabon
27 August
- At 08:15 - EuroIntervention - Long-Term Outcomes of Measured and Predicted Prosthesis–Patient Mismatch Following Transcatheter Aortic Valve Replacement - Thomas Pilgrim et al
- At 08:30 - EHJ - BIVENTRICULAR ARRHYTHMOGENIC CARDIOMYOPATHY: 12 YEARS’ NATURAL HISTORY in a YOUNG ADULT - Chiara Bucciarelli-Ducci
- At 09:42 - EJHF - Effect of dapagliflozin in patients in Asia with heart failure with mildly reduced or preserved ejection fraction: insights from DELIVER - Jawad H. Butt
- At 10:15 - EHJ Open - Cardiovascular Outcomes in Patients with Coronary Artery Disease and Elevated Lipoprotein(a): The OCEAN(a)-Outcomes Trial Population - Arthur Shiyovich
- At 10:15 - EHJ Open - Lipoprotein(a) – the enemy that we still don't know how to defeat. - Maciej Banach
- At 10:30 - EHJ - New-onset Atrial Fibrillation in Chronic Coronary Syndrome Outpatients. Insights from the international CLARIFY registry - Alexandre Gautier
- At 11:40 - EHJ - Coronary revascularization guided by instantaneous wave-free ratio compared to fractional flow reserve: pooled 5-year mortality in the DEFINE-FLAIR and iFR-SWEDEHEART trials - Colin Berry
- At 11:40 - EHJ - Resting indices and Higher Death rates: Is it a play of chance or true effect - Mirvat Alasnag
- At 11:40 - EHJ - Five-year all-cause mortality is increased when revascularization is guided by instantaneous wave free ratio compared to fractional flow reserve: a meta-analysis of iFR-SWEDEHEART and DEFINE FLAIR - Ashkan Eftekhari
- At 11:45 - EHJ - Critical limb-threatening ischemia and microvascular transformation: clinical implications - Petra Korpisalo
- At 15:00 - EHJ - Coronary flow capacity and survival prediction after revascularization: physiological basis and clinical implications - Lance Gould
28 August
- At 00:01 - EJPC - Atrial Fibrillation in Embolic Stroke of Undetermined Source: Role of advanced imaging of left atrial function - Vasiliki Tsampasian
- At 09:15 - EHJ-CVP - Impact of transfusion on platelet aggregation and biomarkers in myocardial infarction patients with anaemia :an ancillary study of the randomized REALITY trial. - Johanne Silvain
- At 10:15 - EHJ - Acute type A aortic dissection: stay and play or load and run? - Martin Czerny
- At 10:15 - EHJ - Type A aortic dissection: optimal annual case volume for surgery - Samuel Heuts
- At 10:15 - EHJ-CI - Prognostic value of myocardial performance index in individuals with type 1 and type 2 diabetes: Thousand & 1 and Thousand & 2 studies. - Hashmat S. Z. Bahrami
- At 11:15 - EHJ Open - Predicting poor neurological outcomes following out-of-hospital cardiac arrest using neuron-specific enolase and neurofilament light chain in patients with and without hemolysis. - Yusuf Abdi Isse
- At 11:45 - EHJ - Quality and transparency of evidence for implantable cardiovascular medical devices assessed by the CORE-MD Consortium - Georgios Siontis (Presenter: Stephan Windecker)
- At 12:00 - EHJ - Atrial pacing minimization in sinus node dysfunction and risk of incident atrial fibrillation: a randomized trial - Mads Brix Kronborg
- At 12:00 - EHJ - Atrial pacing and atrial fibrillation in sinus node dysfunction: a relationship that remains elusive - Ratika Parkash
- At 12:15 - EHJ - Prevalence and Incidence of Diastolic Dysfunction in Atrial Fibrillation: Clinical Implications - Barry A. Borlaug
- At 14:55 - EHJ - Emery-Dreifuss Muscular Dystrophy 1 is associated with high risk of malignant ventricular arrhythmias and end-stage heart failure - Douglas Cannie
- At 15:00 - EHJ - Third generation PCSK9-Inhibitors - Ulrich Laufs
- At 15:00 - EHJ - Frailty and the Risk of Death or Heart Failure Hospitalization in 3429 Patients with Heart Failure from 27 High-, Middle- and Low-Income Countries - Darryl Leong
- At 15:00 - EHJ - FRAILTY: A NEW VITAL SIGN IN HEART FAILURE COMES OF AGE - Finlay A. McAlister
- At 17:15 - EHJ Open - Safety of Cangrelor and Transition to oral P2Y12 Inhibitors in patients undergoing percutaneous coronary intervention: The Arcangelo study - Leo De Luca
The ESC Publications Stand is situated after the Registration Hall in the Lounge & Exchange Area next to the ESC Shop.
We shall be selling 2023 and all preceding years’ pocket guideline titles, as well as sharing key information on all of our journals and books.
Any information or guidance that you require can be requested and as always, we shall be happy to assist you with any ESC publications related challenges.
Access our publishers' highlights
OUP Dedicated ESC Congress 2023 hub that includes content collections and special offers
Our mission: To reduce the burden of cardiovascular disease.